Entera Bio Ltd.
ENTX
Positions held
Your positionsENTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $434.59M | Enterprise value | $421.97M | Trailing P/E | — | Forward P/E | -4.55 |
| PEG | — | Price / book | 17.01 | Beta | 1.41 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -138.9% | ROA | -46.0% | Debt / equity | 0.06 |
| Current ratio | 8.98 | Free cash flow | -$6.68M | Analyst recommendation | strong_buy | Mean target | $9.75 |
| 52w high | $4.20 | 52w low | $0.91 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.3M | -$3.5M | -$3.0M | -$3.2M | -$2.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Operating income | -$4.6M | -$3.5M | -$3.0M | -$3.3M | -$2.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.2M | $0.0M | $0.1M | — |
| Op margin | -27450.0% | -5295.6% | — | -9714.2% | — |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | — |
| Gross margin | 0.0% | 5.0% | — | 24.6% | — |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
2026-10-06 · Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
2026-09-25 · Guggenheim Initiates Entera Bio at Buy With $11 Price Target
2026-08-27 · Correction: Entera to Participate in Upcoming Fall Investor Conferences
2026-08-27 · Entera to Participate in Upcoming Fall Investor Conferences
2026-08-13 · Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
2026-08-10 · Entera Bio shares slip as Q2 loss comes in wider than expected
2026-08-07 · Entera Announces Second Quarter 2026 Financial Results and Business Updates
2026-07-31 · Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-27 · Top Midday Gainers
Price (daily)
Full chart · RSI · MACD · patterns